Moleculin Biotech (FRA:MOL) Change In Receivables : €0.00 Mil (TTM As of Mar. 2024)

View and export this data going back to 2016. Start your Free Trial

What is Moleculin Biotech Change In Receivables?

Moleculin Biotech's change in receivables for the quarter that ended in Mar. 2024 was €0.00 Mil. It means Moleculin Biotech's Accounts Receivable stayed the same from Dec. 2023 to Mar. 2024 .

Moleculin Biotech's change in receivables for the fiscal year that ended in Dec. 2023 was €0.00 Mil. It means Moleculin Biotech's Accounts Receivable stayed the same from Dec. 2022 to Dec. 2023 .

Moleculin Biotech's Accounts Receivable for the quarter that ended in Mar. 2024 was €0.00 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Moleculin Biotech's liquidation value for the three months ended in Mar. 2024 was €6.96 Mil.

Moleculin Biotech Change In Receivables Historical Data

The historical data trend for Moleculin Biotech's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Moleculin Biotech Change In Receivables Chart

Moleculin Biotech Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Change In Receivables

Get a 7-Day Free Trial

Moleculin Biotech Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Change In Receivables	Get a 7-Day Free Trial															-	-	-	-	-

Moleculin Biotech Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.00 Mil.

Moleculin Biotech (FRA:MOL) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Moleculin Biotech's Days Sales Outstanding for the quarter that ended in Mar. 2024 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	0	/	0	*	91
=

2. In Ben Graham's calculation of liquidation value, Moleculin Biotech's accounts receivable are only considered to be worth 75% of book value:

Moleculin Biotech's liquidation value for the quarter that ended in Mar. 2024 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	15.478	-	8.517	+	0.75 * 0	+	0.5 * 0
=	6.96

Moleculin Biotech Change In Receivables Related Terms

Thank you for viewing the detailed overview of Moleculin Biotech's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

Moleculin Biotech (FRA:MOL) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Moleculin Biotech Inc (FRA:MOL) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

MBRX:USA 0K2H:UK

Address

5300 Memorial Drive, Suite 950, Houston, TX, USA, 77007

Website

https://www.moleculin.com

Moleculin Biotech Inc is a clinical-stage pharmaceutical company with a focus on the treatment of highly resistant cancers and viruses through the development of its drug candidates. The company has three core technologies: Annamycin which is a next-generation anthracycline; Immune/Transcription Modulators, of which WP1066 is a member; and Metabolism/Glycosylation Inhibitors, of which WP1122 is a member.

Moleculin Biotech (FRA:MOL) Headlines

No Headlines